Trinomab
Zhuhai
About Trinomab
Trinomab Biotech is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel fully native human monoclonal antibody (mAb) drugs. The company's core technology is known as HitmAb, a proprietary technology platform with differentiated advantages and high efficiency for the discovery of fully native human mAbs against infectious diseases, autoimmune disorders, malignant tumors, and other human diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $148.4M
- Last round: Series Unknown (Nov 2022)
- Website: trinomab.com
- Phone: +86 0756-7263999
Industries & Categories
Biopharma, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/trinomab-88898 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.